1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Fast Market Research Logo

Egypt Pharmaceuticals & Healthcare Report Q4 2012 - New Market Report

New Healthcare research report from Business Monitor International is now available from Fast Market Research

 
PRLog - Nov. 9, 2012 - BMI View: A large population and moderate macroeconomic growth should combine with the political will to increase public healthcare expenditure, which will drive pharmaceutical market growth in Egypt. However, recent events in the country - which can be described as a 'soft coup' by the military - cast doubt on whether there will be a transition of power away from the military and Hosni Mubarak's 'old guard'. If this fails to happen, then it seems possible that the largest growth driver for healthcare spending in the region could fail to materialise. We had forecast that the election of Mohammed Mursi as president would be good for healthcare spending in the country but potentially risky for drugmakers, as the Muslim Brotherhood (MB) candidate had promised to impose a cap on pharmaceutical prices.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/451255_egypt_pharmaceuticals_h...
------------------------------------------------------------

Headline Expenditure Projections

* Pharmaceuticals: EGP18.23bn (US$3.07bn) in 2011 to EGP20.46bn (US$3.82bn) in 2012; +12.3% in local currency terms and +10.3% in US dollar terms. The US dollar forecast is considerably up from Q312 due to new exchange rate calculations.
* Healthcare: EGP62.22bn (US$10.47bn) in 2011 to EGP69.92bn (US$11.56bn) in 2012; +12.4% in local currency terms and +10.4% in US dollar terms. The local currency forecast is broadly in line with Q312.
* Medical devices: EGP3.20bn (US$538mn) in 2011 to EGP3.66bn (US$604mn) in 2012; +14.3% in local currency terms and +12.3% in US dollar terms. The local currency forecast is broadly in line with Q312.

Risk/Reward Rating: In our latest Pharmaceutical Risk/Reward Ratings (RRRs) for the Middle East and Africa (MEA), Egypt ranks 11th, rising by two places since Q312. Egypt's score of 46.9 out of 100 is a quarter-on-quarter increase of about 3%, on account of an increase in its rewards component, though double-digit inflation levels must also be noted. Globally, Egypt is 56th out of 95 markets, between Kazakhstan above it and Morocco below.

Key Trends And Developments

* In June 2012, four Egyptian banks said they will participate in jointly extending an EGP1.5bn (US$248mn) loan facility to fund the public-private partnership (PPP) Healthcare Project, with the construction of a set of hospitals scheduled to start in January 2013. The PPP arrangement will run for 20 years and the division of responsibility will leave almost all clinical service provision to the public sector, with the private sector ensuring the facilities are in place instead can be conducted according to international trade laws.

BMI Economic View: Inflationary pressure in Egypt is set to build in H212, primarily as a result of further currency weakness and a likely hike to domestic energy prices. We forecast consumer price inflation reaching 12.0% by the end of the year, which will have a marked impact on the availability of healthcare finance, two-thirds of which is covered by private sources.

BMI Political View: President Mohammed Mursi had instructed the national assembly to meet as planned despite the ruling military council's order for it to be dissolved. Parliament was closed by the council in June after a ruling to this effect was passed by the supreme court. Speaker Saad al-Katatni said the assembly will met to propose a solution for implementation of the court's ruling and not to defy it. This is the first conflict between the new president and the military, with heightened tensions remaining a threat to democratic transition.

Partial Table of Contents:

SWOT Analysis
- Egypt Pharmaceuticals & Healthcare Industry SWOT
- Egypt Political SWOT
- Egypt Economic SWOT
- Egypt Business Environment SWOT
Pharmaceuticals Risk/Reward Ratings
- Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q412
Egypt - Market Summary
Regulatory Regime
- Drug Registration Transparency Issues Highlighted
- Regulatory Developments
- Intellectual Property Developments
- IP Shortcomings
- Counterfeit Medicines
- Free Trade Agreements
- Pricing Regime
Industry Developments
- Epidemiology
- Communicable Diseases
- Healthcare Sector
- Healthcare Financing
- Healthcare Insurance
- Research & Development Activity
- Clinical Trials
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales, 2008-2016
- Key Growth Factors - Industry
- Table: Overall Healthcare Expenditure, 2008-2016
- Table: Government Healthcare Expenditure, 2008-2016
- Table: Private Healthcare Expenditure, 2008-2016
- Key Growth Factors - Macroeconomic
- Table: Egypt Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales, 2008-2016
- Patented Drug Market Forecast
- Table: Patented Drug Sales, 2008-2016
- Generic Drug Market Forecast
- Table: Generic Drug Sales, 2008-2016
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales, 2008-2016
- Pharmaceuticals Trade Forecast
- Table: Pharmaceutical Trade, 2008-2016
- Medical Device Market Forecast
- Table: Medical Device Sales, 2008-2016
- Other Healthcare Data
- Key Risks To BMI's Forecasts
Competitive Landscape
- Pharmaceutical Industry
- Domestic Pharmaceuticals Sector
- Table: Wholly Or Partially Owned Egyptian Pharmaceutical And Medical Device Companies By Parent Group
- Foreign Pharmaceuticals Sector
- Industry Developments
- Retail Pharmacies
- Herbal And OTC Medicine
Company Profiles
- Domestic Companies
- Egyptian International Pharmaceutical Industries Co (EIPICO)
- South Egyptian Drug Industries (SEDICO)
- Medical Union Pharmaceuticals (MUP)
- Amoun Pharmaceutical Company (APC)
- VASCERA
- Misr Pharmaceuticals
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4512...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.

--- End ---

Click to Share

Contact Email:
***@fastmr.com Email Verified
Source:Fast Market Research, Inc.
Phone:1.800.844.8156
Zip:01267
State/Province:Massachusetts - United States
Industry:Health
Tags:Healthcare, pharmaceuticals, currency
Shortcut:prlog.org/12013799
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share